SCHEMBL561776

SCHEMBL561776

Cc1cc(CNC(=O)c2cc(-c3ccccc3)c(C)n(-c3cccc(C(F)(F)F)c3)c2=O)c(C)o1

nearest known ligand 0.49

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ELANE P08246 13/20 0.49
NOTUM Q6P988 1/20 0.42
CCR1 P32246 2/20 0.41
MAPT P10636 1/20 0.40
PPARG P37231 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31490157 1.00 ELANE (0.49) ELANENOTUMCCR1MAPTPPARG
SCHEMBL561729 0.85 CHRNB2 (0.55) ELANENOTUMCCR1PPARG
SCHEMBL5756113 0.84 ELANE (0.64) ELANENOTUMCCR1MAPT
SCHEMBL561111 0.83 ELANE (0.52) ELANENOTUMMAPTPPARG
SCHEMBL31490174 0.83 ELANE (0.52) ELANENOTUMMAPTPPARG
SCHEMBL561541 0.83 ELANE (0.47) ELANECCR1
SCHEMBL31490320 0.83 ELANE (0.47) ELANECCR1
SCHEMBL31490318 0.82 NPC1 (0.47) ELANENOTUMCCR1
SCHEMBL560933 0.82 NPC1 (0.47) ELANENOTUMCCR1
SCHEMBL562001 0.82 PPARG (0.51) ELANEMAPTPPARGL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501784-B2 2-pyridone derivatives as neutrophil elastase inhibitors and their use ASTRAZENECA AB (SE) 2013-08-06 US claimed
EP-1663973-B3 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE ASTRAZENECA AB (SE) 2019-09-25 EP disclosed
WO-2015114144-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NETHERTON SYNDROME INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-08-06 WO disclosed
EP-1663973-B1 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE ASTRAZENECA AB (SE) 2013-12-25 EP disclosed
US-8501784-B2 2-pyridone derivatives as neutrophil elastase inhibitors and their use ASTRAZENECA AB (SE) 2013-08-06 US disclosed
US-20120035157-A1 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE ASTRAZENECA AB (SE) 2012-02-09 US disclosed
US-8063073-B2 2-pyridone derivatives as neutrophil elastase inhibitors and their use ASTRAZENECA AB (SE) 2011-11-22 US disclosed
US-20070203129-A1 2-Pyridone Derivatives As Neutrophil Elastase Inhibitors And Their Use ASTRAZENECA AB (SE) 2007-08-30 US disclosed
EP-1663973-A1 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE AstraZeneca AB (SE) 2006-06-07 EP disclosed
WO-2005026123-A1 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE ASTRAZENECA AB (SE) 2005-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035157-A1 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE SERPINB1, ELANE, SERPINE1 ELANE 2/4885NOTUM 3528/4885CCR1 192/4885
US-20070203129-A1 2-Pyridone Derivatives As Neutrophil Elastase Inhibitors And Their Use SERPINB1, ELANE, SERPINE1 ELANE 2/4885NOTUM 3343/4885CCR1 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.